New Drug Approval: FDA's Consideration of Evidence from Certain Clinical Trials
DIANE Publishing, 2011 - 38 pages
This is a print on demand edition of a hard to find publication. Before approving a new drug, the FDA assesses a drug's effectiveness. To do so, it examines info. contained in a new drug application (NDA), including data from clinical trials in humans. Several types of trials may be used to gather this evidence. Non-inferiority trials aim to demonstrate that the difference between the effectiveness of a new drug and an active control is small enough to show that the new drug is also effective. FDA has issued guidance on these trials. This report: (1) identifies NDAs for new molecular entities -- potentially innovative new drugs not FDA-approved in any form -- that included evidence from non-inferiority trials; (2) examines the characteristics of these trials; and (3) describes FDA's guidance on these trials. Illustrations.
What people are saying - Write a review
We haven't found any reviews in the usual places.
18 NDAs 2003 Antimicrobial active control drug acute bacterial exacerbations analysis of FDA antimicrobial drugs Antimicrobial Treatment approved based approved drugs basis of evidence basis of non-inferiority biocreep clinical trials confidence interval Cubicin December 31 demonstrate the effectiveness Developing Drugs diabetes mellitus drug application drug types drug’s effectiveness drugs approved Drugs for Treatment drugs treating evidence from non-inferiority evidence of effectiveness exacerbations of chronic example Exjade FDA approved FDA considered FDA documents FDA identified FDA issued FDA officials FDA reviewed FDA’s guidance FDA’s March Fiscal Years 2002 Guidance for Industry indication-specific guidance documents inferiority trials least one non-inferiority March 2010 guidance Marcia Crosse measure the effect molecular entities NDA included evidence NDAs that included non-inferiority margin otitis media particular indication patients pivotal non-inferiority trials placebo provide evidence provide primary evidence reviewed FDA’s Reyataz Submitted from Fiscal submitted to FDA support the approval surrogate endpoint Systemic Lupus Erythematosus Trials Demonstrating